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Adipose-derived mesenchymal stem cells
improve glucose homeostasis in high-fat
diet-induced obese mice
Mingjun Cao1, Qingjie Pan2, Huansheng Dong2, Xinxu Yuan3, Yang Li1, Zhen Sun4, Xiao Dong1*
and Hongjun Wang4*

Abstract
Introduction: Effective therapies for obesity and diabetes are still lacking. The aim of this study was to evaluate
whether a single intravenous infusion of syngeneic adipose-derived mesenchymal stem cells (ASCs) can reduce
obesity, lower insulin resistance, and improve glucose homeostasis in a high-fat diet-induced obese (DIO) mouse
model.
Methods: Seven-week-old C57BL/6 mice were fed a high-fat diet for 20 weeks to generate the DIO mouse model.
Mice were given a single intravenous infusion of ex vivo expanded syngeneic ASCs at 2 × 106 cells per mouse. DIO
or CHOW mice injected with saline were used as controls. Body weights, blood glucose levels, glucose, and insulin
tolerance test results were obtained before and 2 and 6 weeks after cell infusion. Triglyceride (TG), high-density
lipoprotein (HDL), and insulin levels in serum were measured. Expressions of genes related to insulin resistance,
including peroxisome proliferator-activated receptor γ (PPARγ) and insulin receptor (InsR), and inflammation
(IL-6, F4/80, and nucleotide-binding oligomerization domain containing 2, or NOD2), were measured in livers at
mRNA level by real-time-polymerase chain reaction analysis. Beta-cell mass in pancrheases from CHOW, DIO,
and DIO + ASC mice was quantified. GFP+ ASCs were injected, and the presence of GFP+ cells in livers and
pancreases was determined.
Results: DIO mice that had received ASCs showed reduced body weights, reduced blood glucose levels, and
increased glucose tolerance. ASC treatment was found to reduce TG levels and increase serum HDL levels. In
livers, less fat cell deposition was observed, as were increased expression of InsR and PPARγ and reduction in
expressions of IL-6 and F4/80. Treated mice showed well-preserved pancreatic β-cell mass with reduced
expression of F4/80 and TNF-α compared with DIO controls. GFP+ cells were found in liver and pancreas
tissues at 1 and 2 weeks after cell injection.
Conclusions: ASC therapy is effective in lowering blood glucose levels and increasing glucose tolerance in
DIO mice. The protective effects of ASCs arise at least in part from suppression of inflammation in the liver.
In addition, ASCs are associated with better-preserved pancreatic β-cell mass.
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Introduction
Type 2 diabetes (T2D) is a complex metabolic disease
characterized by insulin resistance and pancreatic β-cell
destruction. With the improvement of the standard of
living around the world, the aging of populations, and
the increase in obesity, the incidence of diabetes has
become a global epidemic [1]. Obesity is a leading cause
of insulin resistance and T2D. Therapies that can reduce
obesity and insulin resistance may reduce the onset of
T2D [2].
Mesenchymal stem cells (MSCs) are adult stem cells
that have multipotent differentiation ability. According
to the description of MSCs from the International Society of Cellular Therapy, MSCs attach to standard
plastic tissue culture dishes, express certain cellular
markers (including CD90, CD44, CD105, and the absence of CD45, CD31, etc.,), and can differentiate into
adipocytes, osteocytes, and chondrocytes [3]. MSCs
can be harvested from bone marrow, adipose tissue,
umbilical cord, dental pulp, fetal liver, lung, and many
other kinds of tissues [4]. Adipose-derived stem cells
(ASCs), which can be readily isolated from fat tissue
after liposuction and easily expanded in culture in
large numbers, have become an attractive source for
cell therapy. ASCs have been shown to reduce tissue
damage in various disease situations, including ischemia, neuronal apoptosis, and chemotherapy-induced
ovary dysfunction [5–8]. In animal studies, ASCs differentiated into osteoblasts in vitro and assisted bone
formation after being injected in vivo under the skin
in rats [9]. ASCs injected into damaged periodontal
tissue give rise to alveolar bone, cementum, and periodontal ligaments in Wistar rats [10]. In clinical studies, autologous ASC infusion reversed after traumatic
calvarial defects in a 9-year-old girl [11] and promoted the healing of fistulae associated with Crohn’s
disease [12]. Transplant of ASC-enriched fat grafts,
defined as cell-assistant lipotransfer, showed better
therapeutic effects compared with fat injection alone
in the repair of soft-tissue defects resulting from
tumor resection, trauma, and burns [13, 14].
ASCs have been tested in the treatment of diabetes via
multiple approaches. First, ASCs have directly differentiated into insulin-producing cells through a multiple-stage
differentiation protocol in vitro [15–20]. Differentiated
cells stained positive for dithizone and expressed pdx1, c-peptide, insulin, glucagon, and other β-cell
markers as well as leptin and adiponectin, which
reflected their adipose tissue origins. Insulin production was observed when ASC-derived insulin + cells
were transplanted into streptozotocin (STZ)-induced
diabetic mice, although the amount of insulin secreted
was relatively low compared with insulin secreted by
mature pancreatic islets [21].
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Second, based on their anigogeneic, anti-apoptotic,
and anti-inflammatory properties, ASCs have been cotransplanted with islet grafts to improve graft survival
after transplantation. For example, co-transplantation of
allogeneic mouse islets with autologous ASCs under the
kidney capsule prolonged allogeneic islet survival in
mice [22]. Co-encapsulation of pig islets with ASCs improved oxygenation, neoangiogenesis, and the long-term
function of a subcutaneous of transplanted islets in a
preclinical primate islet transplantation model [23].
Implantation of ASCs and adipose tissue enhanced
subcutaneous grafting of islets in diabetic mice by contributing to islet graft survival and revascularization after
transplantation in diabetic mice [24]. Islets cotransplanted with ASCs pre-treated with a mixture
of hyaluronic, butyric, and retinoic acid manifested
enhanced islet revascularization in diabetic rats [25].
In patients with type 1 diabetes, co-transplantation of
ASC-derived insulin-secreting islets with hematopoietic
stem cells decreased exogenous insulin requirement, increased c-peptide levels, and prevented ketoacidosis [26].
In another clinical trial in the same patient population,
transplantation of ASC-derived insulin+ cells improved
patients’ HB1Ac levels, and decreased serum GAD antibody, without causing adverse effects [27].
Third, intravenous injection of ASCs showed efficacy
in reducing hyperglycemia in various diabetic mouse
models. For example, in STZ-induced diabetic models,
injection of ASCs ameliorated fasting blood glucose and
pancreatic islet damage and improved insulin generation
in Sprague-Dawley rats [28] and C57BL/6 mice [29]. In
the spontaneous non-obese diabetic (NOD) mouse model,
a single injection of ASCs reversed hyperglycemia associated with early-onset diabetes in 78 % of NOD mice, by
regulation of Th1-biased immune response, expansion of
regulatory T cells (Tregs), and reduction of inflammatory
cell infiltration in the pancreas [30].
In addition, ASC infusion showed therapeutic effects
in the treatment of diabetes-related complications. For
example, ASCs from humans or rats ameliorated diabetic retinopathy in diabetic rats [31, 32] and protected podocytes from high-glucose-induced apoptosis
[33]. Stage-specific embryonic antigen-3-positive ASCs
accelerated wound healing associated with type 1 diabetes [34].
The goal of this study was to determine the therapeutic effects and mechanisms of action of ASCs in restoring glucose homeostasis in DIO mice. In this study,
we injected a single dose of ASCs into DIO mice and
assessed the impact of this injection on mouse glucose
disposal and insulin sensitivity. Our goal was to gain
insight into the mechanisms of ASC therapy. We speculate that the tissue-repairing property of ASCs contributed
to their therapeutic effects in the DIO mice.
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Methods
Animals

Male C57BL/6 mice (6 weeks old) and Tg(CAGEGFP)B5Nagy transgenic mice in which the entire
mouse organ system expresses GFP were purchased
from Nanjing Biomedical Research Institute of
Nanjing University (Nanjing, China) and allowed to
adapt to the new environment for 1 week. At 7 weeks
of age, mice were fed with either a high-fat diet
(60 % of calories from fat) or a standard CHOW-fat
diet (10 % of calories from fat) for 20 weeks before
treatment was performed as in a previous study [35].
All animal experiments had been approved by the
Institutional Animal Care and Use Committee at Qingdao
Agricultural University.
ASC collection and characterization

Epididymal fat was dissected from healthy C57BL/6 mice
fed with normal CHOW washed with phosphate-buffered
saline (PBS) and cut into small pieces. Tissues were then
digested with collagenase type 1 (Sigma-Aldrich, St. Louis,
MO, USA) in PBS and incubated in a shaker at 37 °C for
15–30 minutes. At the end of digestion, 10 % fetal bovine
serum (FBS) was added into the mixture to neutralize collagenase. The mixture was then centrifuged at 1200 revolutions per minute (rpm) for 5 minutes to remove floating
adipocytes and liquids. Pellets were re-suspended with
Dulbecco’s modified Eagle’s medium/F12 medium containing 10 % FBS, 1 % penicillin and streptomycin, and
cultured in 37 °C at 5 % CO2 atmosphere. Cells were split
every 7–10 days. Expression of cellular markers (CD105,
CD44, CD29, CD14, and CD31) was determined by
flow cytometry analysis. ASCs were induced to differentiate into adipocytes, osteocytes, and chondrocytes
by using cell differentiation kits from R&D Systems
(Minneapolis, MN, USA) in accordance with the recommendation of the manufacturer. Adipogenic differentiation was determined by Oil Red O staining. Osteogenic
differentiation was determined by Alizarin Red staining. Chondriagenic differentiation was determined by
Toluidine Blue staining as described [36]. GFP+ASCs
were harvested from Tg(CAG-EGFP)B5Nagy transgenic mice and grown ex vivo and used to study migration of injected ASCs. All other reagents were
from Life Technologies (Carlsbad, CA, USA) unless
otherwise stated.
ASC infusion

Mice were put into a mouse restrainer. Cells at passage 3–4 were trypsinized, counted, and re-suspended
in PBS at 1 × 107 cells/ml, and 0.2 ml of cell suspension was slowly infused into the tail vein of each
mouse. Control mice received 0.2 ml of PBS at the
same injection speed.
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Monitoring of mouse behavior, body weight, and blood
glucose levels

Mouse behaviors, including food intake, drinking, licking, and other activities, were observed daily after treatment. Food intake was measured during a 24-hour
period every week. Random blood glucose levels (nonfasting) were measured by using a drop of whole blood
from a tail incision by using a Sannuo glucometer
(Sannuo, Changsha, China). Body weights were measured
after blood glucose measurement at around 9 a.m., two or
three times per week.
Intraperitoneal glucose tolerance and insulin tolerance
test

For intraperitoneal glucose tolerance, mice were fasted
for 16 hours and injected with 2 g/kg of glucose (intraperitoneal). For insulin tolerance test (ITT), mice were
fasted for 5 hours and then injected with one dose of
insulin at 0.75 U/kg (intraperitoneal; Eli Lilly and
Company, Indianapolis, IN, USA). At 0, 15, 30, 60, 90,
and 120 minutes after glucose or insulin injection, a
drop of blood was drawn from the tail vein, and blood
glucose levels were measured.
Tissue harvesting, serum preparation, and blood
biochemistry

At 6 weeks after cell infusion, whole blood was collected
into a heparinized tube. Plasma was separated from whole
blood by centrifugation at 3500 rpm for 15 minutes and
stored at 80 °C for further analysis. Serum triglyceride
(TG), high-density lipoprotein (HDL), and insulin were
measured by using specific reagent kits (Sigma-Aldrich).
For mouse tissue collection, livers and epididymal fat tissue were dissected and weighed. Half of the tissue was cut
into small pieces and snap-frozen in liquid nitrogen for
further analysis. The other half was fixed in 4 % formalin
for histological analysis.
Real-time polymerase chain reaction analysis

Total RNA was extracted from liver and pancreas tissues
by using RNeasy Kit (Qiagen, Venlo, The Netherlands).
RNA was converted into cDNA by reverse transcription.
Expressions of InsR, PPARγ, IL-6, F4/80, TNF-α, and
NOD2 were quantified by reverse transcription-polymerase
chain reaction (RT-PCR) analysis as described previously
[37]. Beta-actin expression was quantified in each sample
and used as an endogenous control. Real-time RT-PCR
primers were purchased from Life Technologies (Invitrogen
Trading Co., Ltd., Shanghai, China).
Hematoxylin-and-eosin staining

Hematoxylin-and-eosin (H&E) staining was performed
as described in a previous study [35]. Fixed tissues were
embedded in paraffin and sectioned into slices of 5 μM
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each. Slides were stained in hematoxylin for 6 minutes,
rinsed with water, and stained with eosin for another
1–2 minutes. Sections were dehydrated in 50 %,
70 %, 80 %, 95 %, and 100 % alcohol solutions,
cleared with xylene, and mounted with a cover slip
onto a labeled glass slide. Slides were observed by
using an Olympus BX51 microscope (Olympus, Tokyo,
Japan), and images were captured by using an Olympus
DP72 digital camera. Diameters of individual fat cells
(n = 200 in each group) were calculated by using CellSens
Standard software (Olympus).
Measurement of pancreatic β-cell mass

Whole pancreas tissue fixed in paraffin was continuously sectioned at 6 μM of thickness. Tissue sections
were collected every 100 μM. About 80–100 sections
were collected for each pancreas. Tissue sections were
then stained with the anti-insulin antibody by immunohistochemistry. After staining, four sections of the
same size were randomly selected in each slide. Insulin + area in each section was calculated, and an average was obtained. For cell-tracking experiments, liver
and pancreas tissues from mice that received GFP+
ASCs were collected at 7 and 14 days after cell infusion. The presence of GFP+ cells was analyzed at
mRNA level by RT-PCR analysis or by immunohistochemistry using the anti-GFP antibody.
Statistical analysis

Unless otherwise stated, data are expressed as mean ±
standard deviation. Data were analyzed by using oneway analysis-of-variance and unpaired Student’s t tests
with Bonferroni correction. P values of less than 0.05
were considered statistically significant.

Results
Generation of DIO mice

We generated DIO mice by using a protocol described
in a previous study [35]. At 20 weeks after feeding with
the high-fat diet, C57BL/6 mice showed significant increase in body weight and reached 42.32 ± 2.63 g, as
compared with 28.72 ± 1.2 g in mice fed a standard diet
(CHOW, Fig. 1a, Table 1). The average blood glucose
level was 170.92 ± 10.31 mg/dl, compared with 126 ±
6.92 mg/dl in CHOW mice (Table 1). No difference in
food intake amount was observed between CHOW and
DIO mice (Fig. 1b). Furthermore, mice showed impaired
glucose disposal after the glucose tolerance test (Fig. 1c
and d). DIO mice also had reduced insulin sensitivity
after ITT and area under the curve above the basal line
(Fig. 1e and f ). It seems that we had set up the DIO
mouse model with decreased glucose tolerance and insulin sensitivity.
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ASC administration reduces body weight and blood
glucose levels and ameliorates insulin resistance
in DIO mice

We first characterized ASCs harvested from adipose
tissue from C57BL/6 mice fed with normal CHOW.
Ex vivo expanded ASCs were fibroblast-like and
showed normal cell growth as bone marrow-derived
MSCs (Fig. 2a). They expressed CD105, CD29, and
CD44 and did not express CD14 and CD45 (Fig. 2b–f).
They could be differentiated into adipocytes, chondrocytes, and osteocytes as identified by standard differentiation methods (Fig. 2g–i).
Next, we assessed whether a single intravenous infusion of ASCs could reduce obesity and insulin resistance
in DIO mice. As shown in Fig 3a, at 20 weeks after feeding with a high-fat diet, DIO mice received intravenous
injections of ASCs at a dose of 2 × 106 cells per mouse.
Compared with the body weights of DIO controls, those
of DIO mice that had received ASCs were slightly reduced. However, the difference between both groups was
not significant (Fig. 3b and c). In contrast, blood glucose
levels of ASCs-treated mice were significantly reduced at
each time point measured (Fig. 3d and e), indicating an
impact of ASC treatment on glucose metabolism in DIO
mice.
ASC injection improves glucose disposal and the effect is
persistent

We next measured the impact of ASC injection on glucose disposal and insulin sensitivity. At 2 weeks after cell
infusion, DIO mice showed faster glucose disposal after
glucose challenge (2 g/kg, Fig. 4a and b, area under the
curve). No difference in insulin sensitivity between the
DIO and DIO + ASC groups was observed at this time
point (Fig. 4c and d).
To determine whether the effect of ASCs on glucose
disposal persists, we performed glucose tolerance test
and ITT at 6 weeks after cell infusion. Mice that received
ASCs showed faster glucose disposal as demonstrated by
significantly lower blood glucoses compared with DIO
controls at various times and area under the curve after
glucose injection (Fig. 4e and f ). In addition, these mice
showed slightly better insulin sensitivity, but the difference was insignificant (Fig. 4g and h). These data suggest
that a single injection of syngeneic ASCs improved glucose disposal and provided protective effects that persisted long after the treatment had ended. In addition,
no significant differences in food intake were observed
among CHOW, DIO, and DIO + ASC group throughout
the study (data not shown).
ASC infusion preserved β-cell mass in DIO mice

To determine the potential mechanisms of action of
ASC injection on glucose disposal, we measured
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Fig. 1 Generation of DIO mice by high-fat diet feeding. a Changes in body weights in C57BL/6 mice fed with normal CHOW (CHOW, n = 14) or
high fat diet (DIO, n = 37). Inset: pictures of CHOW (a) and DIO (b) mice. b Average food intake per mouse per 24-hour period (n = 14 in CHOW
and n = 22 in DIO). c Intraperitoneal glucose tolerance test (GTT) of DIO mice and CHOW controls. d Area under the curve of GTT. e Insulin
tolerance test (ITT) of DIO mice and CHOW mice. f Reverse area under the baseline above the curve, n = 5–10 in each group. *P < 0.05; **P < 0.01,
analysis-of-variance test. CHOW mice fed standard diet, DIO diet-induced obese mice treated with vehicle

pancreatic β-cell mass in CHOW, DIO, and DIO + ASC
mice collected at the end of experiments by staining
whole pancreas sections by using the anti-insulin
antibody. DIO mice showed significantly reduced pancreatic β-cell area compared with CHOW controls. In
Table 1 Body weight and blood glucose of DIO and CHOW
mice
Groups Body weight, g
Ages

7 weeks

21 weeks

CHOW 17.11 ± 2.05 27.4 ± 2.97
DIO

Blood glucose, mg/dl
27 weeks
28.72 ± 1.2

126 ± 6.92

16.96 ± 1.91 32.48 ± 2.97* 42.32 ± 2.63* 170.92 ± 10.31*

CHOW mice fed standard diet, DIO diet-induced obese mice treated
with vehicle
*P < 0.05 compared with CHOW

contrast, mice that received ASCs showed well-preserved
pancreatic β-cell mass comparable to that of CHOW
control mice (Fig. 5a and b). These data showed that ASC
treatment prevented pancreatic β-cell loss that had been
induced by a high-fat diet. MSCs have been shown to
migrate to sites of injury, including pancreatic islets after
intravenous injection [38, 39]. To determine whether
injected ASCs can migrate to the pancreas, we injected
GFP+ ASCs into mice and measured the presence of GFP+
cells after cell infusion. GFP+ cells were observed in pancreases at both 7 and 14 days after cell infusion (Fig. 5c).
We further measured expression of inflammatory cytokines, including TNF-α, NOD2, F4/80, and IL-6, in
pancreases harvested from CHOW, DIO, and DIO +
ASC mice. Our data showed elevated mRNA
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Fig. 2 Characterization of ASCs. a Micrograph of ASCs at passage 1 under light microscopy. Expression of CD29 (b), CD105 (c), CD44 (d), CD14
(e), and CD45 (f) in ASCs as measured by flow cytometry analysis. Red lines represent cells stained with corresponding isotype control, and black
lines represent cells stained with individual antibody. Representative micrographs of ASC-derived adipocyte identified by Oil Red staining (g),
osteocytes by Alizarin Red staining (h), and chondrocytes by Toluidine Blue staining (i). Bar = 100 μM. ASC adipose-derived stem cell

expression of TNF-α, F4/80, and IL-6 in the DIO
group compared with mice from CHOW. In contrast,
ASC-treated pancreases showed significantly reduced
mRNA expression of F4/80 compared with DIO control.
Expression of TNF-α was also reduced compared with
DIO, but the difference was not significant (Fig. 5d–g).
These data suggest that ASC infusion suppressed inflammation in the pancreas, which may have contributed, at
least in part, to preserved pancreatic β-cell mass.
ASC administration reduced adiposity in liver and adipose
tissues

To determine the effects of ASCs on adipocyte infiltration,
liver and epididymal fat tissues were obtained from all mice
in each treatment arm at the end of the experiments. No

differences in liver and epididymal fat weights were observed between DIO control and DIO + ASC groups (Fig. 6a
and b). However, treatment with ASCs improved hepatic
steatosis, and fewer fat cells were observed in livers from
DIO + ASC mice as demonstrated by vacuole area in liver
(Fig. 6d) and by H&E staining (Fig. 6e, upper panel). In adipose tissue, the average diameter of adipocytes in epididymal fat was significantly reduced as well (Fig. 6c and e,
lower panel), suggesting that ASC infusion leads to reduced
adipocyte size caused by high-fat diet.
The effect of ASC infusion on TG and HDL expression and
liver gene expression

We measured serum TG and HDL levels in DIO
mice treated with ASCs or vehicle and in CHOW
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Fig. 3 The effects of ASC infusion on blood glucose levels and body weights. a Treatment schematics of ASC infusion. b Changes in
body weights and c percentages of body weight changes after ASC injection in CHOW (n = 6), DIO control (n = 6), and DIO + ASC
(n = 11) mice. d Random (non-fasting) blood glucose levels and e percentages in blood glucose change in CHOW, DIO, and DIO + ASC
mice. *P < 0.05, **P < 0.01, ***P < 0.01. ASC adipose-derived stem cell, CHOW mice fed standard diet, DIO diet-induced obese mice
treated with vehicle

controls. Feeding with high-fat diet in DIO mice
showed increased TG level and reduced HDL levels
compared with CHOW controls (Fig. 7a and b).
ASC treatment significantly reduced TG levels (P < 0.01)
and increased HDL levels and in DIO mice. High-fat
diet causes a reduction in expressions of InsR and
PPARγ, an increase in expression of inflammationrelated factors (including IL-6), and expression of

F4/80 in livers of DIO mice [35]. We measured expression of those genes in CHOW, DIO, and DIO +
ASC mice. As is evident in Fig. 7c − g, ASC injection restored expression of InsR and PPARγ and reduced expression of IL-6 and F4/80 expression in
livers from DIO mice. There was a reduction of
expression of NOD2 in the DIO + ASC group as
well. However, the difference was not significant.
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Fig. 4 Glucose tolerance and insulin sensitivity in CHOW, DIO, and DIO + ASC mice after treatment. a GTT and b area under the curve of the GTT
test in CHOW, DIO, and DIO + ASC mice 2 weeks after ASC or saline injection. c ITT and d area under the curve of CHOW, DIO, and DIO + ASC
mice at 2 weeks after cell infusion. e GTT and f area under the curve of GTT test in CHOW, DIO, and DIO + ASC mice 6 weeks after ASC or saline
injection. g ITT and h area under the curve of CHOW, DIO, and DIO + ASC mice at 6 weeks after cell infusion, n = 4–5 in each group. *P < 0.05,
**P < 0.01, ***P < 0.01, Student’s t test. ASC adipose-derived stem cell, CHOW mice fed standard diet, DIO diet-induced obese mice treated with
vehicle, GTT glucose tolerance test, ITT insulin tolerance test

Furthermore, the presence of ASCs was confirmed
in the livers at 7 and 14 days after infusion by
measuring mRNA expression of GFP (Fig 7h). These
data suggest that one of the potential effects of
ASC protection is suppression of inflammation in
liver in DIO mice.

Discussion
The most dramatic finding of this study is that a single
infusion of syngeneic ASCs reduced blood glucose levels
and improved glucose disposal in DIO mice. The action
of ASCs was accompanied by a restored lipid profile
(reduced serum TG and increased HDL). In livers, mice
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Fig. 5 Immunofluoroscent staining of pancreases from CHOW, DIO, and DIO + ASC mice. a Representative staining of pancreatic islets from CHOW,
DIO, and DIO + ASC mice. Red represents insulin + cells. Blue stains for nuclei. Bar = 100 μm. b Statistics of islets/β-cell area in mice from each group.
At least three mice were included in each group. c Immunofluorescent staining for GFP+ cells under fluorescent microscope. Arrows pointed to GFP+
cells. Scale bar = 100 μm. At least three mice were analyzed in each group; *P < 0.05, analysis-of-variance test. Relative mRNA expression
of NOD2 (d), F4/80 (e), TNF-α (f), and IL-6 (g) in pancreases of CHOW, DIO, and DIO + ASC (ASC) mice as measured by reverse transcription-polymerase
chain reaction analysis. *P < 0.05. ASC adipose-derived stem cell, CHOW mice fed standard diet, DIO diet-induced obese mice treated with vehicle,
NOD2 nucleotide-binding oligomerization domain containing 2, TNF-α tumor necrosis factor-alpha

in the DIO + ASC group had less fat cell deposition,
higher expressions of InsR and PPARγ, and reduced
expression of IL-6 and F4/80 compared with DIO
control mice. In adipose tissue, DIO + ASC mice had
reduced sizes of adipocytes. In pancreases, a wellpreserved pancreatic β-cell mass was observed. The
protective effects of ASC infusion persisted at least
6 weeks after treatment. One potential explanation
for the protective effects of ASCs lies in the suppression of high-fat diet-induced inflammation in insulintargeting tissues. In obese subjects, macrophages infiltrate into livers and adipose tissue and secrete proinflammatory cytokines (including IL-6 and TNF-α)
and lead to insulin resistance [40]. We found that
fewer fat cell infiltrations in livers in DIO mice received
ASCs. At the molecular level, there were reductions
in F4/80 and IL-6 and in NOD2 in livers. These data
suggest that ASCs improve glucose and insulin sensitivity
by suppressing inflammation in insulin-targeting tissue.

Our results provide evidence that one of the potential
mechanisms accounting for the protection of ASCs may
be their cytoprotective function in pancreatic β cells.
Proper function of islets requires sufficient pancreatic βcell mass and integrity [41]. Beta-cell mass can be reduced by β-cell apoptosis and increased by β-cell replication, neogenesis, or differentiation from stem cells or
other cell types. Compared with β-cell mass in healthy
individuals, β-cell mass in patients with T2D was decreased to around 60 % with the consequent reduction
of glucose-stimulated insulin secretion [42]. Reduced
pancreatic β-cell mass in patients with T2D was believed
to be due mainly to increased β-cell apoptosis instead of
reduction in β-cell replication and neogenesis [43]. We
and other investigators [44] have observed increased βcell mass after bone marrow MSC or ASC injection.
However, whether increased β-cell mass was due to reduced β-cell apoptosis or increased differentiation or
transdifferentiation from ASCs (or both) is still unclear.
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Fig. 6 ASC infusion reduces fat liver and adiposity. a Liver weights of CHOW, DIO, and DIO + ASC mice. b Epididymal fat weights
of CHOW, DIO, and DIO + ASC mice. c Fat bubble diameters (in micrometers) of epididymal adipocytes of CHOW, DIO, and
DIO + ASC mice. d. Statistics of vacuole areas in livers of CHOW, DIO and DIO+ASC mice. e Representative micrographs of
hematoxylin-and-eosin staining of liver and adipose tissue sections from CHOW, DIO, and DIO + ASC mice. ASC adipose-derived stem
cell, CHOW mice fed standard diet, DIO diet-induced obese mice treated with vehicle

Ji et. al showed that both mouse and human insulinpositive cells were found in the pancreases of HFD-fed
mice that had received human MSCs, together with
detectable human insulin circulating in the blood
[44]. Other groups believed that enough pancreatic β
cells could not be generated to maintain euglycemia
after MSC injection and that cellular differentiation
played a minor role in the therapeutic of BM-MSCs
[45, 46]. As ASC infusion led to a rapid (3 days after
cell infusion) reduction in blood glucose levels in our
study, we postulate that one of the major mechanisms
of ASC protection observed was due to reduced pancreatic β-cell death. As shown by others [47] and
confirmed in our study, ASCs after injection can migrate
to an injured pancreas, suppress pro-inflammatory
cytokine expression, and contribute to the survival of
pancreatic islets. Nevertheless, we do not exclude the
possibility that ASCs were indeed differentiated into
pancreatic β cells in our study, since we observed a
well-preserved pancreatic β-cell mass at 6 weeks after
treatment.

In addition, ASC injection promotes expression of
molecules related to insulin sensitivity in the liver. As
shown in our previous study, expression of InsR and
PPARγ was downregulated in livers in DIO mice. We
demonstrated in this study that ASC injection restored
expression of InsR and PPARγ in livers of treated DIO
mouse, indicating that another potential mechanism
responsible for the protective effects of ASCs may be
exerted via its insulin-sensitizing effects, although we
observed only limited improvement in insulin sensitivity
in the present study.
Cells infused from an autologous source are considered safer than cells of allogeneic origins [48].
However, it has been shown that diabetes has a
negative impact on the therapeutic potential of
MSCs. For example, diabetic animals have fewer
MSCs, and MSCs’ ability to proliferate and survive in
these animals is significantly reduced [49]. MSCs from patients with T2D displayed diminished fibrinolytic activity
[50] and defective ischemia recovery [51]. MSCs
from T2D mice displayed reduced post-ischemic
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Fig. 7 Serum lipid levels and gene expression in livers at 6 weeks after treatment. Serum TG (a) and HDL (b) levels were measured in
CHOW, DIO, or DIO + ASC mice at 6 weeks after ASC infusion. Relative mRNA expression of InsR (c), PPARγ (d), IL-6 (e), F4/80 (f), and
NOD2 (g) in livers of CHOW, DIO, and DIO + ASC mice as measured by reverse transcription-polymerase chain reaction analysis. Values
represent relative expression of target gene relative to GAPDH (glyceraldehyde 3-phosphate dehydrogenase) control (National Institutes
of Health ImageJ software). Samples from five or six individual mice were analyzed. Data are mean ± standard deviation; *P < 0.05 and
**P < 0.01, one-way analysis-of-variance test. (h). Relative expression of GFP in livers harvested from CHOW, DIO, and DIO + ASC mice at
7 and 14 days after cell injection. ASC adipose-derived stem cell, CHOW mice fed standard diet, DIO diet-induced obese mice treated
with vehicle

neovascularization in db/db mice [52]. Considering
the above evidence, we used ASCs harvested from
healthy C57BL/6 mice in our study. However, it is
still worth evaluating whether ASCs from obese or
insulin-resistant mice and patients can be used for
therapy in clinical application.

Conclusions
Systemic syngeneic ASC injection reduces blood glucose levels and improves insulin sensitivity in DIO
mice. This was associated with suppressed inflammation in the liver and pancreas and well-preserved pancreatic β-cell mass in treated mice. These findings
reveal mechanistic insights and provide a new therapeutic strategy for the treatment of obesity, insulin
resistance, and T2D.
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